Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Key Highlights
- ➤Immunome granted options for 206,700 shares to 17 new employees
- ➤Immunome granted 103,350 restricted stock units to 17 new employees
- ➤Options carry a $19.59 exercise price and vest over four years
- ➤RSUs vest over four years, with 25% vesting annually
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class cancer therapies, announced today that on November 2, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 206,700 shares of common stock and 103,350 restricted stock units (“RSUs”) to seventeen new employees under the Company’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.